Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Plus Lenalidomide in Follicular Lymphoma
NCT04246086Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2020
- Primary completion
- Sep 2030
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of mosunetuzumab in follicular lymphoma (FL), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities, Percentage of Participants with Adverse Events and 3 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04246086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246086.